Key Insights
The global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is experiencing robust growth, projected to reach a substantial size. The market's Compound Annual Growth Rate (CAGR) of 6.41% from 2019 to 2024 indicates a consistent upward trajectory, driven by several key factors. The increasing complexity of drug development, coupled with the rising demand for specialized services like high-potency API manufacturing and advanced formulation development, are significant contributors to this growth. Pharmaceutical companies are increasingly outsourcing development and manufacturing activities to CDMOs to reduce capital expenditure, accelerate time-to-market, and gain access to specialized expertise and technologies. This trend is particularly pronounced in segments such as high-potency API (HPAPI) manufacturing and complex dosage forms (e.g., injectables), reflecting the shift towards innovative therapies. The expansion of biologics and cell and gene therapies also fuels the demand for specialized CDMO services. Geographic variations exist, with North America and Europe currently holding significant market shares due to established infrastructure and regulatory frameworks. However, the Asia-Pacific region is expected to witness substantial growth in the coming years, driven by rising investments in pharmaceutical R&D and the increasing presence of global CDMO players.
Growth is further fueled by the rising prevalence of chronic diseases globally, necessitating a higher volume of pharmaceutical production. The trend toward personalized medicine and the development of targeted therapies also increases the need for flexible and efficient CDMO partners capable of handling smaller batch sizes and specialized manufacturing processes. While challenges remain, such as stringent regulatory compliance and the need for robust quality control, the overall market outlook remains positive. The consolidation within the CDMO industry, through mergers and acquisitions, is likely to further shape the competitive landscape. The continued focus on innovation and technological advancements within the CDMO sector ensures its role remains pivotal in accelerating drug development and improving patient access to life-saving therapies.
This comprehensive report provides an in-depth analysis of the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market, encompassing market dynamics, growth trends, regional analysis, product landscape, key players, and future outlook. The study period covers 2019-2033, with 2025 as the base year and a forecast period of 2025-2033. This report is invaluable for pharmaceutical companies, investors, and industry professionals seeking to navigate this dynamic market.
-Market.png)
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Dynamics & Structure
The global Pharmaceutical CDMO market, valued at xx Million in 2024, is characterized by a moderately concentrated landscape with several large players and a multitude of smaller, specialized firms. Technological innovation, particularly in areas like cell and gene therapy manufacturing and advanced analytics, is a key driver, while stringent regulatory frameworks and increasing competition influence market dynamics. The market is further segmented by Research Phase (CRO: Pre-clinical, Phase I, Phase II, Phase III, Phase IV) and Service Type (CMO: API Manufacturing, HPAPI, Solid Dose Formulation, Injectable Dose Formulation, Secondary Packaging). Mergers and acquisitions (M&A) activity is frequent, reflecting consolidation trends within the industry.
- Market Concentration: Moderately concentrated, with top 5 players holding approximately xx% market share in 2024.
- Technological Innovation: Focus on automation, AI-driven process optimization, and personalized medicine manufacturing drives growth.
- Regulatory Landscape: Stringent GMP (Good Manufacturing Practice) and other regulatory compliance requirements pose both barriers and opportunities for innovation.
- Competitive Substitutes: Internal manufacturing capabilities within large pharmaceutical companies represent a degree of competitive substitution.
- End-User Demographics: Large pharmaceutical companies, biotech firms, and emerging generic manufacturers are major end-users.
- M&A Trends: Significant M&A activity, with approximately xx deals recorded between 2019 and 2024, indicating consolidation and expansion strategies. Deals have averaged xx Million in value.
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Growth Trends & Insights
The Pharmaceutical CDMO market exhibits robust growth, driven by the outsourcing trend among pharmaceutical companies seeking to streamline operations, reduce capital expenditure, and access specialized expertise. The market size is projected to reach xx Million by 2033, exhibiting a CAGR of xx% during the forecast period (2025-2033). Technological advancements, such as the increasing adoption of continuous manufacturing and process analytical technology (PAT), are accelerating adoption rates. Furthermore, shifting consumer preferences towards targeted therapies and personalized medicine create new growth avenues for CDMOs specializing in these areas. Market penetration of advanced technologies like single-use systems and continuous manufacturing is steadily increasing, exceeding xx% in 2024.
-Market.png)
Dominant Regions, Countries, or Segments in Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
North America currently dominates the Pharmaceutical CDMO market, holding a market share of approximately xx% in 2024, driven by factors such as strong R&D investment, a well-established regulatory framework, and the presence of numerous large pharmaceutical companies. Europe and Asia-Pacific also represent significant market segments. Within service types, API manufacturing and finished dosage formulation (FDF) development and manufacturing command the largest market shares, with solid dose formulations (tablets) accounting for the majority within FDF. By Research Phase, Phase III clinical trials generate the highest demand for CRO services.
- North America: Strong regulatory environment, high R&D spending, presence of major pharmaceutical companies.
- Europe: Well-established pharmaceutical industry, growing focus on biosimilars and cell & gene therapies.
- Asia-Pacific: Rapid growth, increasing outsourcing, cost-effective manufacturing capabilities.
- API Manufacturing: Highest market share due to high demand for raw materials.
- FDF Development & Manufacturing: Significant share driven by increasing demand for ready-to-market formulations.
- Phase III Clinical Trials: Highest demand within CRO services, reflecting the late-stage drug development pipeline.
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Product Landscape
The CDMO market showcases a diverse product landscape encompassing a wide range of services including API manufacturing, formulation development, analytical testing, and packaging. Significant innovation focuses on advanced technologies such as continuous manufacturing, single-use systems, and automated process control, enhancing efficiency and reducing costs. Unique selling propositions include specialized expertise in niche therapeutic areas (e.g., cell and gene therapies, HPAPIs), rapid turnaround times, and flexible manufacturing solutions tailored to specific client needs.
Key Drivers, Barriers & Challenges in Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
Key Drivers:
- Increasing outsourcing by pharmaceutical companies.
- Growing demand for specialized services like cell & gene therapy manufacturing.
- Technological advancements enabling greater efficiency and scalability.
- Regulatory changes promoting innovation.
Key Challenges and Restraints:
- Stringent regulatory compliance requirements.
- Supply chain disruptions impacting raw material availability.
- Intense competition among CDMO providers.
- Capacity constraints for specialized manufacturing technologies. This has resulted in an estimated xx% increase in lead times for certain services in 2024.
Emerging Opportunities in Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market
- Expansion into emerging markets (e.g., Latin America, Africa).
- Focus on niche therapeutic areas, like personalized medicine and advanced therapies.
- Development of innovative packaging and delivery systems.
- Adoption of digital technologies for enhanced efficiency and data analytics.
Growth Accelerators in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry
The CDMO market's long-term growth is fueled by ongoing technological breakthroughs in drug development, manufacturing, and analytical testing. Strategic partnerships and collaborations between CDMOs and pharmaceutical companies are crucial. Expansion into new markets and therapeutic areas, particularly those related to personalized medicine and biologics, offer considerable potential.
Key Players Shaping the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Market
- LSK Global Pharma Service Co Ltd
- Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc)
- Hangzhou Tigermed Consulting Co Ltd
- Famar SA
- PAREXEL International Corporation
- CMIC Holdings Co Ltd
- PRA Health Sciences Inc (Icon PLC)
- Lonza Group
- Pfizer CentreSource
- SGS Life Science Services SA
- Samsung Bioepis Co Ltd
- Jubilant Pharmova Ltd
- WuXi AppTec Inc
- Tesa Labtec GmbH (TESA SE)
- Patheon Inc (Thermo Fisher Scientific Inc)
- Syneos Health Inc
- IQVIA Holdings Inc
- ARX LLC
- Tapemark
- Catalent Inc
- Boehringer Ingelheim Group
- Novotech Pty Ltd
- LabCorp Drug Development
- Aenova Holding GmbH
- Recipharm AB
- Sagimet Biosciences (3V Biosciences Inc)
- Baxter Biopharma Solutions (Baxter International Inc)
- Quanticate Ltd
Notable Milestones in Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Sector
- January 2024: FAMAR and Lavipharm announce a new collaboration, expanding FAMAR's European CDMO presence.
- January 2024: Pluri launches "pluriCDMO," a new cell therapy manufacturing division with a new GMP facility.
- October 2023: IQVIA and Argenx collaborate on innovative pharmacovigilance services.
In-Depth Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Market Outlook
The future of the Pharmaceutical CDMO market appears bright, characterized by sustained growth driven by technological innovation, strategic partnerships, and increasing outsourcing trends within the pharmaceutical industry. The continued development and adoption of advanced manufacturing technologies, coupled with the expansion into new therapeutic areas, will drive market expansion and create numerous strategic opportunities for existing and new players alike. The market is expected to show a sustained CAGR exceeding xx% over the next decade, offering significant potential for stakeholders.
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segmentation
-
1. Service Type CMO Segment
-
1.1. Active P
- 1.1.1. Small Molecule
- 1.1.2. Large Molecule
- 1.1.3. High Potency (HPAPI)
-
1.2. Finished
-
1.2.1. Solid Dose Formulation
- 1.2.1.1. Tablets
- 1.2.1.2. Others (Capsules, Powders, etc.)
- 1.2.2. Liquid Dose Formulation
- 1.2.3. Injectable Dose Formulation
-
1.2.1. Solid Dose Formulation
- 1.3. Secondary Packaging
-
1.1. Active P
-
2. Research Phase CRO Segment
- 2.1. Pre-clinical
- 2.2. Phase I
- 2.3. Phase II
- 2.4. Phase III
- 2.5. Phase IV
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
-
2. Europe
- 2.1. United Kingdom
- 2.2. Germany
- 2.3. France
- 2.4. Italy
-
3. Asia
- 3.1. China
- 3.2. India
- 3.3. Japan
- 3.4. Australia and New Zealand
-
4. Latin America
- 4.1. Brazil
- 4.2. Mexico
- 4.3. Argentina
-
5. Middle East and Africa
- 5.1. United Arab Emirates
- 5.2. Saudi Arabia
- 5.3. South Africa
- 6. North America
- 7. Europe
- 8. Asia
- 9. Australia and New Zealand
- 10. Latin America
- 11. Middle East and Africa
-Market.png)
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 6.41% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Outsourcing Volume by Big Pharmaceutical Companies; Advent of CDMO Model into the Market; Increasing Investment in R&D
- 3.3. Market Restrains
- 3.3.1. Increasing Lead Time and Logistics Costs; Stringent Regulatory Requirements; Capacity Utilization Issues Affecting the Profitability of CMOs
- 3.4. Market Trends
- 3.4.1. Increasing Investment in R&D Drives the Market
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 5.1.1. Active P
- 5.1.1.1. Small Molecule
- 5.1.1.2. Large Molecule
- 5.1.1.3. High Potency (HPAPI)
- 5.1.2. Finished
- 5.1.2.1. Solid Dose Formulation
- 5.1.2.1.1. Tablets
- 5.1.2.1.2. Others (Capsules, Powders, etc.)
- 5.1.2.2. Liquid Dose Formulation
- 5.1.2.3. Injectable Dose Formulation
- 5.1.2.1. Solid Dose Formulation
- 5.1.3. Secondary Packaging
- 5.1.1. Active P
- 5.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 5.2.1. Pre-clinical
- 5.2.2. Phase I
- 5.2.3. Phase II
- 5.2.4. Phase III
- 5.2.5. Phase IV
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia
- 5.3.4. Latin America
- 5.3.5. Middle East and Africa
- 5.3.6. North America
- 5.3.7. Europe
- 5.3.8. Asia
- 5.3.9. Australia and New Zealand
- 5.3.10. Latin America
- 5.3.11. Middle East and Africa
- 5.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 6. North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 6.1.1. Active P
- 6.1.1.1. Small Molecule
- 6.1.1.2. Large Molecule
- 6.1.1.3. High Potency (HPAPI)
- 6.1.2. Finished
- 6.1.2.1. Solid Dose Formulation
- 6.1.2.1.1. Tablets
- 6.1.2.1.2. Others (Capsules, Powders, etc.)
- 6.1.2.2. Liquid Dose Formulation
- 6.1.2.3. Injectable Dose Formulation
- 6.1.2.1. Solid Dose Formulation
- 6.1.3. Secondary Packaging
- 6.1.1. Active P
- 6.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 6.2.1. Pre-clinical
- 6.2.2. Phase I
- 6.2.3. Phase II
- 6.2.4. Phase III
- 6.2.5. Phase IV
- 6.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 7. Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 7.1.1. Active P
- 7.1.1.1. Small Molecule
- 7.1.1.2. Large Molecule
- 7.1.1.3. High Potency (HPAPI)
- 7.1.2. Finished
- 7.1.2.1. Solid Dose Formulation
- 7.1.2.1.1. Tablets
- 7.1.2.1.2. Others (Capsules, Powders, etc.)
- 7.1.2.2. Liquid Dose Formulation
- 7.1.2.3. Injectable Dose Formulation
- 7.1.2.1. Solid Dose Formulation
- 7.1.3. Secondary Packaging
- 7.1.1. Active P
- 7.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 7.2.1. Pre-clinical
- 7.2.2. Phase I
- 7.2.3. Phase II
- 7.2.4. Phase III
- 7.2.5. Phase IV
- 7.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 8. Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 8.1.1. Active P
- 8.1.1.1. Small Molecule
- 8.1.1.2. Large Molecule
- 8.1.1.3. High Potency (HPAPI)
- 8.1.2. Finished
- 8.1.2.1. Solid Dose Formulation
- 8.1.2.1.1. Tablets
- 8.1.2.1.2. Others (Capsules, Powders, etc.)
- 8.1.2.2. Liquid Dose Formulation
- 8.1.2.3. Injectable Dose Formulation
- 8.1.2.1. Solid Dose Formulation
- 8.1.3. Secondary Packaging
- 8.1.1. Active P
- 8.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 8.2.1. Pre-clinical
- 8.2.2. Phase I
- 8.2.3. Phase II
- 8.2.4. Phase III
- 8.2.5. Phase IV
- 8.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 9. Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 9.1.1. Active P
- 9.1.1.1. Small Molecule
- 9.1.1.2. Large Molecule
- 9.1.1.3. High Potency (HPAPI)
- 9.1.2. Finished
- 9.1.2.1. Solid Dose Formulation
- 9.1.2.1.1. Tablets
- 9.1.2.1.2. Others (Capsules, Powders, etc.)
- 9.1.2.2. Liquid Dose Formulation
- 9.1.2.3. Injectable Dose Formulation
- 9.1.2.1. Solid Dose Formulation
- 9.1.3. Secondary Packaging
- 9.1.1. Active P
- 9.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 9.2.1. Pre-clinical
- 9.2.2. Phase I
- 9.2.3. Phase II
- 9.2.4. Phase III
- 9.2.5. Phase IV
- 9.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 10. Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 10.1.1. Active P
- 10.1.1.1. Small Molecule
- 10.1.1.2. Large Molecule
- 10.1.1.3. High Potency (HPAPI)
- 10.1.2. Finished
- 10.1.2.1. Solid Dose Formulation
- 10.1.2.1.1. Tablets
- 10.1.2.1.2. Others (Capsules, Powders, etc.)
- 10.1.2.2. Liquid Dose Formulation
- 10.1.2.3. Injectable Dose Formulation
- 10.1.2.1. Solid Dose Formulation
- 10.1.3. Secondary Packaging
- 10.1.1. Active P
- 10.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 10.2.1. Pre-clinical
- 10.2.2. Phase I
- 10.2.3. Phase II
- 10.2.4. Phase III
- 10.2.5. Phase IV
- 10.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 11. North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 11.1.1. Active P
- 11.1.1.1. Small Molecule
- 11.1.1.2. Large Molecule
- 11.1.1.3. High Potency (HPAPI)
- 11.1.2. Finished
- 11.1.2.1. Solid Dose Formulation
- 11.1.2.1.1. Tablets
- 11.1.2.1.2. Others (Capsules, Powders, etc.)
- 11.1.2.2. Liquid Dose Formulation
- 11.1.2.3. Injectable Dose Formulation
- 11.1.2.1. Solid Dose Formulation
- 11.1.3. Secondary Packaging
- 11.1.1. Active P
- 11.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 11.2.1. Pre-clinical
- 11.2.2. Phase I
- 11.2.3. Phase II
- 11.2.4. Phase III
- 11.2.5. Phase IV
- 11.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 12. Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 12.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 12.1.1. Active P
- 12.1.1.1. Small Molecule
- 12.1.1.2. Large Molecule
- 12.1.1.3. High Potency (HPAPI)
- 12.1.2. Finished
- 12.1.2.1. Solid Dose Formulation
- 12.1.2.1.1. Tablets
- 12.1.2.1.2. Others (Capsules, Powders, etc.)
- 12.1.2.2. Liquid Dose Formulation
- 12.1.2.3. Injectable Dose Formulation
- 12.1.2.1. Solid Dose Formulation
- 12.1.3. Secondary Packaging
- 12.1.1. Active P
- 12.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 12.2.1. Pre-clinical
- 12.2.2. Phase I
- 12.2.3. Phase II
- 12.2.4. Phase III
- 12.2.5. Phase IV
- 12.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 13. Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 13.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 13.1.1. Active P
- 13.1.1.1. Small Molecule
- 13.1.1.2. Large Molecule
- 13.1.1.3. High Potency (HPAPI)
- 13.1.2. Finished
- 13.1.2.1. Solid Dose Formulation
- 13.1.2.1.1. Tablets
- 13.1.2.1.2. Others (Capsules, Powders, etc.)
- 13.1.2.2. Liquid Dose Formulation
- 13.1.2.3. Injectable Dose Formulation
- 13.1.2.1. Solid Dose Formulation
- 13.1.3. Secondary Packaging
- 13.1.1. Active P
- 13.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 13.2.1. Pre-clinical
- 13.2.2. Phase I
- 13.2.3. Phase II
- 13.2.4. Phase III
- 13.2.5. Phase IV
- 13.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 14. Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 14.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 14.1.1. Active P
- 14.1.1.1. Small Molecule
- 14.1.1.2. Large Molecule
- 14.1.1.3. High Potency (HPAPI)
- 14.1.2. Finished
- 14.1.2.1. Solid Dose Formulation
- 14.1.2.1.1. Tablets
- 14.1.2.1.2. Others (Capsules, Powders, etc.)
- 14.1.2.2. Liquid Dose Formulation
- 14.1.2.3. Injectable Dose Formulation
- 14.1.2.1. Solid Dose Formulation
- 14.1.3. Secondary Packaging
- 14.1.1. Active P
- 14.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 14.2.1. Pre-clinical
- 14.2.2. Phase I
- 14.2.3. Phase II
- 14.2.4. Phase III
- 14.2.5. Phase IV
- 14.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 15. Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 15.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 15.1.1. Active P
- 15.1.1.1. Small Molecule
- 15.1.1.2. Large Molecule
- 15.1.1.3. High Potency (HPAPI)
- 15.1.2. Finished
- 15.1.2.1. Solid Dose Formulation
- 15.1.2.1.1. Tablets
- 15.1.2.1.2. Others (Capsules, Powders, etc.)
- 15.1.2.2. Liquid Dose Formulation
- 15.1.2.3. Injectable Dose Formulation
- 15.1.2.1. Solid Dose Formulation
- 15.1.3. Secondary Packaging
- 15.1.1. Active P
- 15.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 15.2.1. Pre-clinical
- 15.2.2. Phase I
- 15.2.3. Phase II
- 15.2.4. Phase III
- 15.2.5. Phase IV
- 15.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 16. Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 16.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 16.1.1. Active P
- 16.1.1.1. Small Molecule
- 16.1.1.2. Large Molecule
- 16.1.1.3. High Potency (HPAPI)
- 16.1.2. Finished
- 16.1.2.1. Solid Dose Formulation
- 16.1.2.1.1. Tablets
- 16.1.2.1.2. Others (Capsules, Powders, etc.)
- 16.1.2.2. Liquid Dose Formulation
- 16.1.2.3. Injectable Dose Formulation
- 16.1.2.1. Solid Dose Formulation
- 16.1.3. Secondary Packaging
- 16.1.1. Active P
- 16.2. Market Analysis, Insights and Forecast - by Research Phase CRO Segment
- 16.2.1. Pre-clinical
- 16.2.2. Phase I
- 16.2.3. Phase II
- 16.2.4. Phase III
- 16.2.5. Phase IV
- 16.1. Market Analysis, Insights and Forecast - by Service Type CMO Segment
- 17. North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 17.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 17.1.1.
- 18. Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 18.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 18.1.1.
- 19. Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 19.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 19.1.1.
- 20. Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 20.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 20.1.1.
- 21. Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 21.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 21.1.1.
- 22. Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2031
- 22.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 22.1.1.
- 23. Competitive Analysis
- 23.1. Global Market Share Analysis 2024
- 23.2. Company Profiles
- 23.2.1 LSK Global Pharma Service Co Ltd
- 23.2.1.1. Overview
- 23.2.1.2. Products
- 23.2.1.3. SWOT Analysis
- 23.2.1.4. Recent Developments
- 23.2.1.5. Financials (Based on Availability)
- 23.2.2 Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc )
- 23.2.2.1. Overview
- 23.2.2.2. Products
- 23.2.2.3. SWOT Analysis
- 23.2.2.4. Recent Developments
- 23.2.2.5. Financials (Based on Availability)
- 23.2.3 Hangzhou Tigermed Consulting Co Ltd
- 23.2.3.1. Overview
- 23.2.3.2. Products
- 23.2.3.3. SWOT Analysis
- 23.2.3.4. Recent Developments
- 23.2.3.5. Financials (Based on Availability)
- 23.2.4 Famar SA
- 23.2.4.1. Overview
- 23.2.4.2. Products
- 23.2.4.3. SWOT Analysis
- 23.2.4.4. Recent Developments
- 23.2.4.5. Financials (Based on Availability)
- 23.2.5 PAREXEL International Corporation
- 23.2.5.1. Overview
- 23.2.5.2. Products
- 23.2.5.3. SWOT Analysis
- 23.2.5.4. Recent Developments
- 23.2.5.5. Financials (Based on Availability)
- 23.2.6 CMIC Holdings Co Ltd
- 23.2.6.1. Overview
- 23.2.6.2. Products
- 23.2.6.3. SWOT Analysis
- 23.2.6.4. Recent Developments
- 23.2.6.5. Financials (Based on Availability)
- 23.2.7 PRA Health Sciences Inc (Icon PLC)
- 23.2.7.1. Overview
- 23.2.7.2. Products
- 23.2.7.3. SWOT Analysis
- 23.2.7.4. Recent Developments
- 23.2.7.5. Financials (Based on Availability)
- 23.2.8 Lonza Group
- 23.2.8.1. Overview
- 23.2.8.2. Products
- 23.2.8.3. SWOT Analysis
- 23.2.8.4. Recent Developments
- 23.2.8.5. Financials (Based on Availability)
- 23.2.9 Pfizer CentreSource
- 23.2.9.1. Overview
- 23.2.9.2. Products
- 23.2.9.3. SWOT Analysis
- 23.2.9.4. Recent Developments
- 23.2.9.5. Financials (Based on Availability)
- 23.2.10 SGS Life Science Services SA
- 23.2.10.1. Overview
- 23.2.10.2. Products
- 23.2.10.3. SWOT Analysis
- 23.2.10.4. Recent Developments
- 23.2.10.5. Financials (Based on Availability)
- 23.2.11 Samsung Bioepis Co Ltd
- 23.2.11.1. Overview
- 23.2.11.2. Products
- 23.2.11.3. SWOT Analysis
- 23.2.11.4. Recent Developments
- 23.2.11.5. Financials (Based on Availability)
- 23.2.12 Jubilant Pharmova Ltd
- 23.2.12.1. Overview
- 23.2.12.2. Products
- 23.2.12.3. SWOT Analysis
- 23.2.12.4. Recent Developments
- 23.2.12.5. Financials (Based on Availability)
- 23.2.13 WuXi AppTec Inc
- 23.2.13.1. Overview
- 23.2.13.2. Products
- 23.2.13.3. SWOT Analysis
- 23.2.13.4. Recent Developments
- 23.2.13.5. Financials (Based on Availability)
- 23.2.14 Tesa Labtec GmbH (TESA SE)
- 23.2.14.1. Overview
- 23.2.14.2. Products
- 23.2.14.3. SWOT Analysis
- 23.2.14.4. Recent Developments
- 23.2.14.5. Financials (Based on Availability)
- 23.2.15 Patheon Inc (Thermo Fisher Scientific Inc )
- 23.2.15.1. Overview
- 23.2.15.2. Products
- 23.2.15.3. SWOT Analysis
- 23.2.15.4. Recent Developments
- 23.2.15.5. Financials (Based on Availability)
- 23.2.16 Syneos Health Inc
- 23.2.16.1. Overview
- 23.2.16.2. Products
- 23.2.16.3. SWOT Analysis
- 23.2.16.4. Recent Developments
- 23.2.16.5. Financials (Based on Availability)
- 23.2.17 IQVIA Holdings Inc
- 23.2.17.1. Overview
- 23.2.17.2. Products
- 23.2.17.3. SWOT Analysis
- 23.2.17.4. Recent Developments
- 23.2.17.5. Financials (Based on Availability)
- 23.2.18 ARX LLC
- 23.2.18.1. Overview
- 23.2.18.2. Products
- 23.2.18.3. SWOT Analysis
- 23.2.18.4. Recent Developments
- 23.2.18.5. Financials (Based on Availability)
- 23.2.19 Tapemark
- 23.2.19.1. Overview
- 23.2.19.2. Products
- 23.2.19.3. SWOT Analysis
- 23.2.19.4. Recent Developments
- 23.2.19.5. Financials (Based on Availability)
- 23.2.20 Catalent Inc
- 23.2.20.1. Overview
- 23.2.20.2. Products
- 23.2.20.3. SWOT Analysis
- 23.2.20.4. Recent Developments
- 23.2.20.5. Financials (Based on Availability)
- 23.2.21 Boehringer Ingelheim Group
- 23.2.21.1. Overview
- 23.2.21.2. Products
- 23.2.21.3. SWOT Analysis
- 23.2.21.4. Recent Developments
- 23.2.21.5. Financials (Based on Availability)
- 23.2.22 Novotech Pty Ltd
- 23.2.22.1. Overview
- 23.2.22.2. Products
- 23.2.22.3. SWOT Analysis
- 23.2.22.4. Recent Developments
- 23.2.22.5. Financials (Based on Availability)
- 23.2.23 LabCorp Drug Development
- 23.2.23.1. Overview
- 23.2.23.2. Products
- 23.2.23.3. SWOT Analysis
- 23.2.23.4. Recent Developments
- 23.2.23.5. Financials (Based on Availability)
- 23.2.24 Aenova Holding GmbH
- 23.2.24.1. Overview
- 23.2.24.2. Products
- 23.2.24.3. SWOT Analysis
- 23.2.24.4. Recent Developments
- 23.2.24.5. Financials (Based on Availability)
- 23.2.25 Recipharm AB
- 23.2.25.1. Overview
- 23.2.25.2. Products
- 23.2.25.3. SWOT Analysis
- 23.2.25.4. Recent Developments
- 23.2.25.5. Financials (Based on Availability)
- 23.2.26 Sagimet Biosciences (3V Biosciences Inc )*List Not Exhaustive
- 23.2.26.1. Overview
- 23.2.26.2. Products
- 23.2.26.3. SWOT Analysis
- 23.2.26.4. Recent Developments
- 23.2.26.5. Financials (Based on Availability)
- 23.2.27 Baxter Biopharma Solutions (Baxter International Inc )
- 23.2.27.1. Overview
- 23.2.27.2. Products
- 23.2.27.3. SWOT Analysis
- 23.2.27.4. Recent Developments
- 23.2.27.5. Financials (Based on Availability)
- 23.2.28 Quanticate Ltd
- 23.2.28.1. Overview
- 23.2.28.2. Products
- 23.2.28.3. SWOT Analysis
- 23.2.28.4. Recent Developments
- 23.2.28.5. Financials (Based on Availability)
- 23.2.1 LSK Global Pharma Service Co Ltd
List of Figures
- Figure 1: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Breakdown (Million, %) by Region 2024 & 2032
- Figure 2: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 3: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 4: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 5: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 6: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 7: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 8: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 9: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 10: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 11: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 12: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 13: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 14: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 15: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 16: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 17: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 18: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 19: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 20: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 21: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 22: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 23: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 24: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 25: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 26: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 27: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 28: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 29: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 30: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 31: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 32: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 33: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 34: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 35: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 36: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 37: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 38: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 39: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 40: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 41: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 42: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 43: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 44: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 45: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 46: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 47: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 48: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 49: North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 50: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 51: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 52: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 53: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 54: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 55: Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 56: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 57: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 58: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 59: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 60: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 61: Asia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 62: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 63: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 64: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 65: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 66: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 67: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 68: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 69: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 70: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 71: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 72: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 73: Latin America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
- Figure 74: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Service Type CMO Segment 2024 & 2032
- Figure 75: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Service Type CMO Segment 2024 & 2032
- Figure 76: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Research Phase CRO Segment 2024 & 2032
- Figure 77: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Research Phase CRO Segment 2024 & 2032
- Figure 78: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million), by Country 2024 & 2032
- Figure 79: Middle East and Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 3: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 4: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Region 2019 & 2032
- Table 5: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 6: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 7: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 8: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 9: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 10: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 11: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 12: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 13: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 14: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 15: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 16: Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 17: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 18: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 19: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 20: United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 21: Canada Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 22: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 23: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 24: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 25: United Kingdom Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 26: Germany Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 27: France Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 28: Italy Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 29: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 30: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 31: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 32: China Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 33: India Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 34: Japan Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 35: Australia and New Zealand Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 36: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 37: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 38: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 39: Brazil Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 40: Mexico Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 41: Argentina Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 42: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 43: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 44: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 45: United Arab Emirates Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 46: Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 47: South Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 48: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 49: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 50: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 51: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 52: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 53: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 54: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 55: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 56: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 57: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 58: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 59: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 60: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 61: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 62: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
- Table 63: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Service Type CMO Segment 2019 & 2032
- Table 64: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Research Phase CRO Segment 2019 & 2032
- Table 65: Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Revenue Million Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market?
The projected CAGR is approximately 6.41%.
2. Which companies are prominent players in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market?
Key companies in the market include LSK Global Pharma Service Co Ltd, Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc ), Hangzhou Tigermed Consulting Co Ltd, Famar SA, PAREXEL International Corporation, CMIC Holdings Co Ltd, PRA Health Sciences Inc (Icon PLC), Lonza Group, Pfizer CentreSource, SGS Life Science Services SA, Samsung Bioepis Co Ltd, Jubilant Pharmova Ltd, WuXi AppTec Inc, Tesa Labtec GmbH (TESA SE), Patheon Inc (Thermo Fisher Scientific Inc ), Syneos Health Inc, IQVIA Holdings Inc, ARX LLC, Tapemark, Catalent Inc, Boehringer Ingelheim Group, Novotech Pty Ltd, LabCorp Drug Development, Aenova Holding GmbH, Recipharm AB, Sagimet Biosciences (3V Biosciences Inc )*List Not Exhaustive, Baxter Biopharma Solutions (Baxter International Inc ), Quanticate Ltd.
3. What are the main segments of the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market?
The market segments include Service Type CMO Segment, Research Phase CRO Segment.
4. Can you provide details about the market size?
The market size is estimated to be USD 243.29 Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Outsourcing Volume by Big Pharmaceutical Companies; Advent of CDMO Model into the Market; Increasing Investment in R&D.
6. What are the notable trends driving market growth?
Increasing Investment in R&D Drives the Market.
7. Are there any restraints impacting market growth?
Increasing Lead Time and Logistics Costs; Stringent Regulatory Requirements; Capacity Utilization Issues Affecting the Profitability of CMOs.
8. Can you provide examples of recent developments in the market?
January 2024 - A new collaboration was announced jointly by FAMAR and Lavipharm, two leading pharmaceutical companies. FAMAR is a leading provider of development and manufacturing services for pharmaceutical and cosmetic products (CDMO) and one of the major CDMO players in Europe. Lavipharm is a research and development (R&D) company that manufactures, imports, sells, and distributes pharmaceuticals and healthcare products in Greece.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market?
To stay informed about further developments, trends, and reports in the Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
